All Ordinaries Index (ASX: XAO) shares closed up 0.7% on Friday.

That helped the All Ords post a gain of 1.2% for the first week of trading in 2023.

Investors will certainly welcome this start to the new year after All Ordinaries shares dropped 7.2% in 2022. Though it may be too early to hope for a return to 2021 levels, when the index gained 13.6% over the calendar year.

While the 1.2% gains represent a solid start to 2023, these three All Ordinaries shares delivered far more in the first week.

As you'll note below, all three of the top performers this past week suffered heavy losses in 2022. With them now leading the charge in the new year, investors look to be doing some bargain hunting.

Top 3 All Ordinaries share gainers this week

The third-best performer in the first week of trade was gold miner Alkane Resources Ltd (ASX: ALK).

Alkane has a market cap of $383 million.

Like the other top-performing All Ordinaries shares covered in this article, the Alkane share price fell heavily in 2022, down 41%.

Unlike the other two stocks, Alkane did release positive price-sensitive news this week. The Alkane share price closed up 11% on Thursday after the company upgraded its FY2023 production guidance at its Tomingley Gold Operations in New South Wales.

This helped Alkane deliver a 24% gain in the first week of trading in 2023, finishing the week at 67 cents per share.

The number two spot goes to diagnostic imaging company Cyclopharm Ltd (ASX: CYC).

Cyclopharm has a market cap of $125 million.

The All Ordinaries healthcare share tumbled 29% in 2022 but is certainly off to a better start this year. Cyclopharm closed the week up 25% at $1.46 per share.

Which bring us to the best All Ordinaries share performer in the first week of 2023, financial services company Harmoney Corp Ltd (ASX: HMY).

Harmoney has a market cap of $58.4 million.

The stock lost a painful 76% in 2022 but staged a strong rally to kick off 2023, gaining 30% in the first week of trade. Harmoney closed the week trading for 57 cents per share.

The post Can you guess the top 3 performing All Ordinaries shares in the first week of trade? appeared first on The Motley Fool Australia.

Cyclopharm Limited (ASX: CYC) shares are on the rise today after the company released a trading update earlier today. In early afternoon trading, the Cyclopharm share price is trading 3.03% higher at $1.70.

Shares in the company were up by more than 7% in earlier trade after hitting an intraday high of $1.775.

Lets take a look at what Cyclopharm announced.  

Record first-half revenue

The Cyclopharm share price is getting a boost today after the company released unaudited accounts for the 6 months ending 30 June 2021.

The report was highlighted by record half-year revenue of approximately $8.1 million. The result reflects a 45% increase from the prior corresponding period.

In addition, Cyclopharm highlighted that revenues from Patient Administration Sets are expected to be 20% higher than the first half of 2020.

Cyclopharm noted that the revenue performance reflects the continuing shift in the mix of consumable sales to higher margin markets.

The company also highlighted that net cash at the half-year is expected to be in excess of $30 million. As a result, Cyclopharm confirmed its intention to pay a dividend of 0.5 cents per share at the half-year.

Cyclopharm managing director, James McBrayer said of the results:

Cyclopharm's strong revenue growth across all our product and service lines in our established markets is driving the business to significantly outperform the results in the first halves of 2020 and 2019.

Cyclopharm share price snapshot

Cyclopharm is a biotech company that operates in the diagnostic imaging field, specialising in lung health. The company's flagship Technegas technology is used across 60 countries throughout the world.

The Cyclopharm share price was travelling well in 2021 until last week when it tumbled around 40% following a market update.

The company announced it had received negative feedback from the United States Food and Drug Administration (FDA), sending investors running for the hills.

According to the announcement, the FDA noted that Cylopharm's Technegas could not be approved as it stands.

The FDA gave Cyclopharm a list of items it needs to address within 12 months to potentially gain approval. Cyclopharm assured the market it will be able to address the required issues and still hopes to secure FDA approval in 2022.

Despite today's bounce, the Cyclopharm share price remains more than 32% lower for the year.

The post Cyclopharm (ASX:CYC) share price jumps on trading update appeared first on The Motley Fool Australia.

Cyclopharm Limited (ASX: CYC) shares are taking an absolute pummelling today. At the time of writing, the Cyclopharm share price is crashing 41.61% lower to $1.60.

Below, we take a look at the ASX healthcare company's latest market update.

What did Cyclopharm announce?

The Cyclopharm share price is crumbling after the company reported on the latest developments regarding approval of its Technegas medical imaging drug in the United States.

The radiopharmaceutical company said the United States Food and Drug Administration (FDA) had provided a Complete Response Letter (CRL) for its New Drug Application (NDA).

In that response, the FDA said it could not approve the NDA for Technegas as it stands. The agency gave Cyclopharm a list of items it needs to address within 12 months to potentially gain approval. The company stated it expects to be able to sort out the required issues and hopes to still secure approval in 2022.

Commenting on the FDA response, James McBrayer, Cyclopharm CEO said:

While the elements in the USFDA's CLR letter are attainable within the required timeframe, we are disappointed with this news of the additional technical information requests. Effectively the CLR has extended the expected approval timeframe by around nine months.

We have complete confidence that we can address these matters and do what is required to expedite this process. We now have clarity as to what will satisfy the USFDA's expectations and will commence work on the response immediately.

McBrayer said Cyclopharm is working closely with the FDA in order to address the outstanding elements still required.

The company updated its guidance for gaining FDA approval from the second half of 2021 to the second half of 2022. It said this delay will not influence its ability to fund the rest of the approval process. The US is a core part of the company's growth plans, which it estimates to be worth US$180 million (AU$237 million) per year.

Cyclopharm already sells Technegas in 60 other nations, with over 4.4 million patients using the medical imaging drug so far.

Cyclopharm share price snapshot

With today's early losses factored in, Cyclopharm shares have only gained around 19% over the past 12 months, compared to the 25% gains posted by the All Ordinaries Index (ASX: XAO).

Year to date, the Cyclopharm share price is now down by 36%.

The post Why the Cyclopharm (ASX:CYC) share price is crashing 42% lower appeared first on The Motley Fool Australia.

The Cyclopharm Limited (ASX: CYC) share price is dipping today after the company released its 2021 AGM Presentation.

Cyclopharm shares are down 1% to $2.82 at the time of writing, after gaining more than 10% over the past week.

Cyclopharm Ltd is an Australia-based company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development.

Highlights from Cyclopharm's market update

Cyclopharm reported significant metrics in its AGM, noting record group sales revenue in 2020 of $14.7 million, up 4.2% on 2019. It recorded $2.2 million of new third‐party distribution revenue in its Technegas distribution network.

Overall, Technegas sales rebounded by 51.4% in the second half of 2020, after a pandemic-impacted first half. The company reported a $5.8 million net loss before tax. The company's February 2021 capital raising placement was oversubscribed, raising $33 million in total.

Cyclopharm AGM Chair's address

Cyclopharm Chair, David Heaney, expanded on the company's rebound from COVID-19.

2020 was a pivotal year for Cyclopharm. Despite the challenges we faced from a global coronavirus pandemic, we have expanded our global footprint to  include sales into over 60 countries, and proudly, our Technegas products have now been used in over 4.3 million patient procedures globally. We also commenced operations as a distributor of third party products in Europe, leveraging our existing distribution capabilities.

Together with our existing Technegas revenues, this new income stream enabled Cyclopharm to report record revenues in 2020 of $14.7 million. Our strong underlying sales performance supported the Board's decision to maintain our full year dividend at 1.0 cent per share.

Background on Cyclopharm's business model

Cyclopharm operates through two segments. Its Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. Meanwhile, its Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The company generates maximum revenue from the Technegas segment.

Cyclopharm share price snapshot

The Cyclopharm share price has had a good run recently, up 10% in the past week, 11% the past month, 14% in 2021 so far and 146% over the past 12 months. 

The post Why is the Cyclopharm (ASX:CYC) share price down today? appeared first on The Motley Fool Australia.

The Cyclopharm Limited (ASX: CYC) share price was sent soaring today after the company announced a business update.

Cyclopharm shares went as high as 14.41% in afternoon trade before closing 6.78% up at $2.52 per share.

What Cyclopharm does

Cyclopharm is an ASX-listed radiopharmaceutical company headquartered in New South Wales. It currently has a market capitalisation of just over $203 million.

As stated on the company's website, "the company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes."

The health company aims to achieve this objective through the provision of its core radiopharmaceutical product, Technegas, which is used in functional lung ventilation imaging.

What happened?

Today, the Cyclopharm share price went soaring after the company announced an update on its progress towards gaining United States Food and Drug Administration (USFDA) approval. The company needs USFDA approval in order to begin sales of Technegas, its flagship product, in the US.

The company announced that its phase 3 trials have met their Primary and Secondary Efficacy Endpoints in September of last year. As such, it will continue its ongoing "positive" dialogue with the USFDA in order to get its approval of Technegas.

Based on these discussions, the company remains highly confident the approval process is on track to be completed in the second half of FY21.

Cyclopharm also updated its guidance for FY20 revenue. The company stated that despite the challenges of COVID-19, revenue is expected to be in line with that of FY19, which was approximately $14 million.

US market entry

With the impending approval of Technegas, Cyclopharm has begun undertaking activities to ensure it is well placed to rapidly roll out its product. These activities include building inventory reserves, finalising agreements for third party distribution, service and installation, and administrative support.

According to Cyclopharm, the existing market for nuclear medicine ventilation in the US is estimated to be roughly US$90 million annually.

Based on Cyclopharm's experience in the Canadian market, it remains confident that Technegas can achieve a 50% share of the USA market over 2 to 3 years, with an 80% share representing around 480,000 procedures per annum achievable over a 5 to 7 year period.

The post Why the Cyclopharm (ASX:CYC) share price popped 6% today appeared first on The Motley Fool Australia.

The Cyclopharm Limited (ASX: CYC) share price continues to bask in the glory of its clinical trial announcement released earlier this week.

Shares in the diagnostic imaging technology developer surged 28.2% to a record high of $2.50 in the last hour of trade, taking its total gain to 78.6% in three days.

In contrast, the All Ordinaries (Index:^AORD) (ASX:XAO) and the S&P/ASX 200 Index (Index:^AXJO) have lost more than 1% each at the time of writing.

Successful trial triggers Cyclopharma share price surge

Cyclopharma announced on Tuesday that the Independent Data Monitoring Efficacy Committee (DEMC) has unanimously recommended that the company's Technegas Phase 3 trial (CYC-009) be stopped as it was a success.

This means Cyclopharma can suspend the trial. Following consultation with the US Food and Drug Administration (USFDA), the CYC‐009 study will be terminated with orderly formal site close out and notification to reviewing Investigational Review Boards.

"Given over three decades of clinical use, hundreds of clinical papers and references in practice guidelines featuring the benefits of Technegas, we were always confident of a positive outcome," said the company's chief executive James McBrayer.

"The recommendation handed down by the DEMC overnight Australian time validates our confidence in our Technegas technology and further de‐risks our pathway to USFDA approval to sell Technegas in the USA market in 2021."

Poised to join prestigious ASX club

If Cyclopharma gains final USFDA approval for its lung test, which looks likely, it will join the league of other successful ASX medical device companies.

These include the Nanosonics Ltd. (ASX: NAN) share price, RESMED/IDR UNRESTR (ASX: RMD) share price and Cochlear Limited (ASX: COH) share price.

What Cyclopharma's technology does

Cyclopharma's Technegas technology uses very fine radioactive carbon, which is inhaled by a patient. This allows detailed images to be taken by a gamma or single photon emission computed tomography (SPECT) camera.

The technology can be used to diagnose COPD, asthma, pulmonary hypertension and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.

Shareholders breathing easy

The CYC‐009 clinical trial is a prospective, 240‐patient, non‐inferiority comparison against Xe‐133. The Phase 3 trial design was approved under a Special Protocol Assessment granted on 4 October 2016.

The impact of COVID-19 slowed patient recruitment and only 204 patients (or 85% of the targets number) were imaged. This prompted the USFDA to call in an independent committee to review the efficacy data.

The positive recommendation from the DEMC does not guarantee that the USFDA will give CYC-009 its final tick of approval, but this is likely as federal regulators are often guided by independent panel of experts.

The post Why the Cyclopharma (ASX:CYC) share price surged to record high today appeared first on The Motley Fool Australia.

The Cyclopharm Limited (ASX: CYC) share price has rocketed out of the gates this morning after the company announced another milestone in its quest to gain approval in the lucrative US market.

After jumping as much as 21.83% higher in early trade, Cyclopharm shares have pulled back somewhat to currently sit 9.16% higher at $1.55 per share. This takes its market capitalisation at the time of writing to around $121 million.

About Cyclopharm

Cyclopharm is a radiopharmaceutical company primarily involved in the field of nuclear medicine. It operates in the diagnostic imaging field, specialising in lung health.

The company's core radiopharmaceutical product is Technegas, a structured ultra-fine dispersion of radioactive labelled carbon used in lung ventilation imaging.

Cyclopharm has a global presence, distributing its products in 57 countries throughout the world with more than 1,500 medicine departments utilising Technegas.

Why is the Cyclopharm share price rocketing?

This morning, Cyclopharm announced that it has been granted approval to file status for its new drug application (NDA) for Technegas. 

As a result, Technegas will now proceed to the next stage of the US Food and Drug Administration (FDA) approval process – review. The review stage will involve a 10-month qualitative review where the FDA will assess "the safety and efficacy of Technegas as a nuclear medicine functional lung ventilation imaging agent"

The NDA approval announced today marks the 3rd milestone in the company's 7-step pathway to achieving FDA approval for Technegas.

Commenting on today's update, CEO James McBrayer said:

We are absolutely thrilled with the progress we are making in completing the steps to gain approval to market Technegas in the USA. This Approval to File follows our successful lodgment in March and a full USD $2.9m Fee Waiver designation in April. Today's notification confirms that we are on track for Technegas to be approved early next year.

As for Cyclopharm's total addressable market opportunity, Mr McBrayer stated:

The United States is the largest nuclear medicine market in the world. We estimate the size of the US market for Technegas in diagnosing the presence of Pulmonary Embolism (PE) is approximately US$90 million in sales per annum. Following USFDA approval to sell into that market, we will be targeting a 50% share of this market in the first 2 to 3 years, rising to 80% over 5 to 7 years.

The company also has plans to expand Technegas beyond PE into new applications, such as the diagnosis and monitoring of chronic obstructive pulmonary disease (COPD), asthma, and other respiratory diseases.

The post Cyclopharm share price rockets 22% higher on FDA application approval appeared first on The Motley Fool Australia.

Dorsavi Ltd (ASX: DVL) has a market capitalisation of $66 million. It develops technology that accurately measures human movements in elite sports, occupational health and safety, and clinical settings.

Dorsavi's solutions include both sensors and software. The company earns both upfront product revenue and ongoing recurring fees. However, the breakdown of these two separate income streams is not currently disclosed.

The business has three key markets of Australia, Europe and the USA. Australia remains the largest revenue contributor at $1.1 million for the first half of 2017, but Europe and USA are far more significant in terms of growth potential. Indeed, the USA division recorded $0.5 million of revenue in the first half of 2017, exceeding total full-year 2016 revenue for the region.

For the first half of 2017, Dorsavi grew sales revenue by 33.8% to $1.7 million and reduced losses by 59% to $1.3 million. The company is well funded with $11.7 million in cash which given current growth rates, gross margins and cash burn should be sufficient to reach profitability in my opinion.

My one concern with Dorsavi is that wearable technology is a competitive field. I wouldn't be surprised to see the likes of Fitbit or even Apple become direct competitors to Dorsavi in the future.

Mach7 Technologies Ltd (ASX: M7T) has a market capitalisation of $54.9 million and develops healthcare imaging software. It also has a small medical 3D printing business.

The company's software is installed at 529 sites in 11 countries and customer contracts typically last five years with an increasing proportion of revenue paid monthly rather than upfront. It is costly for customers to switch providers and so combined with the transition to monthly invoicing, it is reasonable to view the revenue that Mach7 earns as recurring in nature.

In February, Mach7 announced that it expects to achieve profitability at the earnings before interest, tax, depreciation and amortisation (EBITDA) level in 2017 on the back of surging revenues. Revenue for the first half of 2017 rose 40% to $4.8 million on a pro forma basis. The company's growth potential is significant as its products address a multi-billion dollar global market.

As predominantly a software company, Mach7 earns very high gross margins – 94% for the first half of 2017. Consequently, most of the revenue growth for the period converted to incremental profits. EBITDA losses fell from $3.3 million in the prior corresponding period to $1.4 million for the first half of 2017.

Clearly, significant revenue growth is required in the second half of 2017 for Mach7 to achieve a breakeven result for the year and so there is a good chance that the company will fall short. Mach7 had $5.8 million in cash at 31 December 2016 so should not need to raise any further equity assuming this goal is met.

Unlike the above two businesses, Cyclopharm Limited (ASX: CYC) is already profitable and yet has the lowest market capitalisation of the three at $47.8 million. The company's main product is Technegas, a lung imaging technology whereby the patient inhales radioactive gas.

Cyclopharm also enjoys an attractive annuity like income stream. Technegas consists of a generator and consumable Patient Administration Sets (PAS). Generator sales are one-off, high value and low margin, whereas PAS sales are recurring, low value and high margin. As the base of installed generators grows, so too does Cyclopharm's high-margin PAS recurring revenue stream.

Technegas is currently approved for use in most developed global markets outside the US for testing Pulmonary emboli (PE). PE is where arteries in the lungs become blocked by a blood clot. Cyclopharm is currently pursuing regulatory approval in the US as well for Chronic Obstructive Pulmonary Disease (COPD) which is a much bigger market than PE.

Revenue rose 14% to $14.4 million in 2016 and underlying EBITDA from the Techegas business increased 15% to $3.4 million. However, statutory EBITDA was just $1.5 million largely because the company spent $1.1 million on progressing regulatory approvals.

And this is the risk with Cyclopharm. The company could potentially waste years of profits on pursuing FDA approval with no guarantee of success. On the other hand, if Technegas is approved for the US market or for COPD, then the stock would be worth multiples of its current price.

The post 3 speculative micro-cap shares that could make you a fortune appeared first on The Motley Fool Australia.

It's difficult for the members of the ASX Top 20 Index to double, triple or quadruple revenues in a short period of time – but smaller companies can do that – if you find the right ones that is.

Here are three that investors might want to consider adding to a solid portfolio…

FSA Group Ltd (ASX: FSA)

FSA Group provides debt solutions and lending services to consumers – mainly to help consolidate debt and sort out their finances – and has a market cap of around $130 million. It's the largest provider of debt agreements in Australia, originating 48% of all agreements in Australia in 2015. Back in May, the company announced that it had sold its factoring business for around $10 million in after-tax cash. Add to that the company's cheap price – at $1.05, the company is trading on a trailing P/E ratio of 9.7x and paying a dividend yield of more than 6% – fully franked.

Joyce Corporation Ltd (ASX: JYC)

A retailer of bedding through the Bedshed franchise chain (~30 stores), Joyce Corp has a market cap of around $36 million, but had substantial cash ($13.7m) and property (~$5m) on its balance sheet. The company also owns 51% of KWB Group (Kitchen Connection and Wallspan) – a retailer and installer of custom kitchens and wardrobes – and recently announced the acquisition of 51% of Lloyds Online auctions for $6 million. Lloyds is expected to add $10 million in revenues to Joyce Corp and boost total sales across the network to more than $170 million in the 2017 financial year. (Note: Not all of that is attributable to Joyce Corp).

The company also pays a solid and growing fully franked dividend, and at the current share price of $1.32, looks reasonably cheap.

Cyclopharm Limited (ASX: CYC)

It's not often that you find a biotech stock that generates growing revenues, is profitable, debt free and also pays out dividends but Cyclopharm is one. The company's primary product is Technegas – a lung imaging technology widely used around the world to diagnose the presence of blood clots. Cyclopharm also expects to have another product coming onto the market next year – Ultralute – a product that extends the useful life of nuclear isotopes by up to 50%.

Cyclopharm has a market cap of just $72 million, but generated $4.8m in net profit in the 2015 financial year and paid a 1 cent fully franked dividend.

But the biggest catalyst could be ahead with Technegas commencing phase III trials in the US in 2012. The US has the potential to become the company's biggest global market for Technegas.

The post 3 cheap diversified micro-cap stocks for your portfolio appeared first on The Motley Fool Australia.

But that doesn't mean all stocks listed on the Australian Stock Exchange have gone nowhere. In fact, 10 companies have seen their share prices soar by more than 50%, and 4 of these have more than doubled.

Cynata Therapeutics Ltd (ASX: CYP) has leapt 228% since early February to $1.18. The stem cell research company achieved a major breakthrough, achieving commercial-scale manufacture of stem cell products. As you can well imagine, that has major implications if Cynata can go on and commercialise its technology.

AtCor Medical Holdings Limited (ASX: ACG) is up 120% to 21 cents. AtCor received Category 1 approval for its SphygmoCor blood pressure system in the US. Colleague Brendon Lau covered the news in more detail here.

Cyclopharm Limited (ASX: CYC) jumped 116.9% to 64 cents, after reporting record sales of $12 million and an record net profit of $4m – although that included a $2.65 million legal settlement. Cyclopharm is a nuclear medicine company, with products including Technegas for lung imaging. Has the company turned the corner like CEO James McBrayer thinks it has?

Cokal Ltd (ASX: CKA) has seen its shares soar 128.6% to 10 cents, despite the company being a coal explorer. In late February, Cokal received construction and operational approval for its Bumi Barito Mineral (BBM) Project port facilities in Indonesia. BBM is expected to produce a premium coking coal over a period of more than 15 years.

TNG Limited (ASX: TNG) has gained 77.8% to trade around 17 cents currently. TNG is focused on developing its flagship Mount Peak Vanadium-Titanium-Iron project near Alice Springs, which the company says can deliver revenues of $13.6 billion. Yesterday TNG signed an offtake agreement with Korean metals group WOOJIN IND. Co. for up to 60% of forecast production.

Aeris Environmental Ltd (ASX: AEI) shares have climbed 50.7% to trade around 51 cents currently. Aeris is an expert in the removal of bacteria and mould that naturally builds up in air-conditioning, cold storage and bulk water systems and then protects the asset from further recontamination. Aeris recently reported strong growth in purchase orders and potential pipeline of large scale projects.

1-Page Limited (ASX: 1PG) has jumped 66.7% to $1.65 after the company signed a number of major deals, including giant US retailer Amazon for its 1-Page sourcing and referral engine. 1-Page offers companies a new way to hire prospective employees.

Joyce Corporation Ltd (ASX: JYC) has gained 50.8% to trade at 95 cents. The company owns a chain of bedding stores under the BedShed brand. Joyce recently sold a property for $25 million, and the board is considering a suitable return to shareholders of the settlement proceeds, expected to be a franked special dividend of 5 cents per share each year for the next three years. Joyce is forecast to pay 10.5 cents in total this year.

Anatarra Lifesciences Ltd (ASX: ANR) is up 57.6% to 52 cents. Anatarra develops non-antibiotic solutions for gastrointestinal diseases in animals and humans, and recently reported a successful trial on a pig farm of its Detach product. Anatarra is now focused on registering Detach in Europe and the USA, and hopes to launch Detach in 2016 in Australia.

Last but not least is Digital CC Ltd (ASX: DCC) which is up 66.7% to 14 cents. The company is a digital payments company – the first bitcoin focused company listed on a major exchange. Bitcoin is a digital currency that is usually in the news for the wrong reasons, and there's no guarantee that Bitcoin will be successful.

The post 10 stocks up by more than 50% in the past month appeared first on The Motley Fool Australia.